B+
Bull case
20%
Probability
Target price
$300.00
Analysis reference price unavailable
Analysis 2026-07-20 · RankAlpha Sentiment Codex
JNJ
Johnson JohnsonBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 result strengthened the operating floor: sales grew 6.6%, adjusted EPS grew 4.7%, and management raised both sales and EPS guidance. Post-print analyst actions were broadly constructive, including Guggenheim Buy at $270, Bernstein's target increase to $261, and Freedom Capital's upgrade with a $280 target.
Posture
Constructive
Lead driver
Sentiment
What changed
7 setup hits (3d) with net bullish as of 2026-09-10.
What can break
Analyst revisions were constructive but mixed, with Bernstein retaining Market Perform; broader estimate-revision coverage remains limited.
Momentum
53
Value
62
Sentiment
63
Setup hits (3d)
7 · Net Bullish
AI TargetsBase $275.00 · Bull $300.00 · Bear $225.00Analysis 2026-07-20; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $282.10
Why
Momentum53 · Δ7d -21.8
Value62 · Δ7d -0.0
Sentiment63 · Δ7d +6.2
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 7 setup hits (3d) with net bullish as of 2026-09-10.
- • Sentiment remains the lead driver in the composite, 7D delta +6.2.
Contradictions & invalidation
- • Analyst revisions were constructive but mixed, with Bernstein retaining Market Perform; broader estimate-revision coverage remains limited.
- • Pipeline, regulatory, launch, and commercial-uptake execution remain necessary to sustain the raised outlook. [#SEC-8K-2026-07-15]
- • The stock initially fell 2.69% on the release date before recovering over the next two sessions, suggesting the beat was not a clean re-rating catalyst.
Catalyst clock
2026-07-15
Q2 results and raised 2026 outlook
Lead driver: Sentiment · See AI snapshot
Momentum
53
9% active weight
Current posture
7d trendSoftening
Δ7d
-21.8
Δ21d
-5.6
Value
62
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.9
Sentiment
63
62% active weight
Current posture
7d trendImproving
Δ7d
+6.2
Δ21d
+2.0
Why this grade
Composite grade B. Momentum 53.0 / Value 61.8 / Sentiment 62.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-20. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$275.00
Analysis reference price unavailable
Analysis 2026-07-20 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$225.00
Analysis reference price unavailable
Analysis 2026-07-20 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$632.29B
Beta
0.34
Shares Out
2.41B
P/E (TTM)
19.7
P/S (TTM)
5.34
P/FCF (TTM)
66.85
Rev YoY
+6.6%
EPS YoY
-0.9%
Gross Margin
+68.0%
Op Margin
+27.0%
Net Debt
$29.23B
Current Ratio
1.09
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data